RenovoRx receives Nasdaq extension to Dec 28, 2026 to regain $1 minimum bid price compliance

RenovoRx, Inc.

Received Nasdaq notice on July 1, 2026 granting additional 180-day compliance period until Dec 28, 2026.
Previously reported deficiency on Dec 31, 2025 for failing to meet $1.00 minimum bid price requirement.
Must have closing bid price ≥ $1.00 for 10 consecutive business days during second period to regain compliance.
If not compliant by Dec 28, 2026, Nasdaq will delist common stock; company may appeal to Hearings Panel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.